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Abstract Administration of biomacromolecular drugs in ef-
fective quantities from conventional vaginal rings is hampered
by poor drug permeability in the polymers from which rings
are commonly constructed. Here, we report the formulation
development and testing of rod insert rings for sustained re-
lease of the candidate antiretroviral peptides T-1249 and
JNJ54310516-AFP (JNJ peptide), both of which have poten-
tial as HIV microbicides. Rod inserts were prepared compris-
ing antiviral peptides T-1249 or JNJ peptide in combination
with a hydrophilic excipient (sodium chloride, sodium gluta-
mate, lactose or zinc acetate) dispersed at different loadings
within a medical grade silicone elastomer. The inserts were
tested for weight change and swelling when immersed in sim-
ulated vaginal fluid (SVF). Dye migration into the inserts was
also assessed visually over 28 days. In vitro release of T-1249
and JNJ peptide from rings containing various insert types
was tested. Weight change and degree of swelling of rods
immersed in SVF was dependent on the type and concentra-
tion of excipient present. The rods displayed the following
rank order in terms of weight change: sodium glutamate >
zinc acetate≈ sodium chloride > lactose. The weight change
and degree of swelling of the inserts did not correlate with the
level of dye uptake observed. In vitro release of T-1249 was
improved through addition of lactose, sodium chloride and
sodium glutamate, while release of JNJ peptide was improved
through addition of sodium chloride or sodium glutamate.
Sustained release of hydrophobic peptides can be achieved
using a rod insert ring design formulated to include a hydro-
philic excipient. Release rates were dependent upon the type
of excipient used. The degree of release improvement with
different inserts partially reflects their ability to imbibe sur-
rounding fluid and swell in aqueous environments.
Keywords HIV-1microbicide . Silicone elastomer vaginal
ring . Rod insert ring
Introduction
Vaginal rings delivering small molecule antiretrovirals are cur-
rently attracting interest as a long-acting strategy for reducing
heterosexual transmission of human immunodeficiency virus
type 1 (HIV-1) [1–4]. For example, a dapivirine-releasing ring
is currently undergoing phase III clinical testing in Africa [5,
6]. The potential benefits of vaginal rings over conventional
vaginal formulations e.g. gels and creams, include coital inde-
pendence, improved adherence and the ability to deliver mi-
crobicide compound(s) over extended time periods [1, 3, 7].
Results from the CAPRISA trial highlighted the impact that
user non-adherence can have onmicrobicide effectiveness [8].
For a successful microbicide strategy to be effective in wide-
spread use, it should be easy to use and be able to deliver
microbicides at sufficient rates to ensure protection over a
minimum period of time [7].
Marketed vaginal rings are typically composed of hydro-
phobic polymers, such as silicone elastomer or ethylene vinyl
acetate copolymer, with the crystalline drug substances either
homogeneously dispersed throughout the ring (a matrix-type
design) or located in a drug-loaded central core which is
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covered by a rate-controlling polymer membrane (a reservoir-
type design). In both designs, drug release is dependent upon
permeation of the drug through the polymer network, and
therefore requires a degree of drug solubility and diffusivity
within the polymer [7, 9, 10]. This drug permeation mecha-
nism generally lends itself to daily release rates within the low
microgram to low milligram range for small hydrophobic
molecules when formulated within hydrophobic polymers.
By contrast, large and/or hydrophilic molecules tend to exhibit
very poor release characteristics. A number of high molecular
weight compounds are currently in development as potential
microbicides, including anti-HIVantibodies, the CCR5 inhib-
itor chemokine analogue 5P12-RANTES and various peptide-
based fusion inhibitors [11–13]. New ring formulations are
therefore needed for effective vaginal administration of such
molecules.
Attempts to improve the release of high molecular weight
drugs from hydrophobic polymers by incorporation of hydro-
philic excipients have been reported previously [14–16].
However, this approach is generally not applicable to vaginal
rings owing to the very considerable swelling that occurs
when large amounts of fluid are absorbed into the ring at the
high excipient loadings required to give clinically significant
release rates. Alternatively, loading very high concentrations
of the high molecular weight drug into the ring device might
offer enhanced release rates. However, the relative expense of
most biomolecular drugs is a major constraint, and substantial
burst effects would be anticipated.
Recently, we reported a rod insert vaginal ring design for
sustained release of macromolecules, comprising a non-
medicated silicone elastomer body with cavities for insertion
of various rod-shaped drug carriers (Fig. 1) [17]. The benefits
of this system include a greatly reduced amount of drug re-
quired per ring (as only the inserts contain the drug), and the
ability to easily modify drug release through the use of hydro-
philic excipients that swell and dissolve in contact with water.
In addition, the high temperatures normally required in man-
ufacture of the ring body can be avoided when formulating
heat-sensitive drugs. Previous work has demonstrated that
peptide- and protein-based drugs can be released from
silicone-based rods with the release rate varied through hydro-
philic excipient addition [18–24]. Other groups are also inves-
tigating similar modified ring strategies to deliver macromo-
lecular actives [25, 26].
Here, we compare the impact of hydrophilic excipients on
the release rates of two hydrophobic polypeptide microbicide
candidates. T-1249 (molecular weight 5037 g/mol) is a 39-
residue peptide that inhibits fusion of HIV to the host target
cell by blocking the conformational change in the HIV enve-
lope protein gp41 that is necessary for the fusion of the viral
and the target cell membranes. JNJ54310516-AFP (JNJ pep-




Platinum-catalysed, medical grade, silicone elastomer two-
part kit (LSR9-9509-30) was supplied by NuSil Silicone
Technology Inc. (Carpinteria, USA). JNJ54310516-AFP was
provided by Janssen Research and Development (Beerse,
Belgium). T-1249 was obtained from Trimeris (Durham,
USA). HPLC-grade acetonitrile and isopropanol (IPA), along
with trifluoroacetic acid (TFA), sodium chloride (NaCl), sodi-
um glutamate (NaGlu), zinc acetate (Zn(CH2COOH)2), lac-
tose and methylene blue dye were obtained from Sigma-
Aldrich (Gillingham, UK). NaCl, NaGlu, Zn(CH2COOH)2
and lactose were milled with a mortar and pestle and passed
through a 180 μm-sieve before use. Medical grade PVC tub-
ing was obtained from NuncNalgene (NY, USA). Simulated
vaginal fluid (pH 4.2; SVF) was prepared using analytical-
grade reagents according to a previously described recipe
[27]. HPLC-grade water was obtained using a Millipore
Direct-Q 3 UV Ultrapure Water System (Watford, UK).
Covered rods and rod insert manufacture
Dispersed mixtures (total weight 2.0 g) comprising Parts A
and B LSR9-9508-30 addition cure silicone elastomer mix
(1:1) and from 0 to 50 % w/w of one of NaCl, NaGlu,
Zn(CH3COO)2 or lactose were prepared using a DAC 150
FVZ-K Speedmixer (30 s, 3000 rpm). The mixtures were
injected into medical grade PVC tubing (3.0 or 4.0 mm inter-
nal diameter) via a disposable plastic syringe and allowed to
cure for at least 24 h at room temperature before being cut into
7.6-mm length sections to produce covered rods. Peptide-
loaded rod inserts were manufactured in a similar fashion
incorporating either 20 or 40 % w/w excipient and 1 % w/w
peptide. The PVC tubing was removed entirely upon curing
for peptide-loaded rod inserts.
Rod insert ring manufacture
Parts A and B LSR9-9508-30 addition cure silicone
elastomer mix were mixed in equal quantities before
injecting onto specifically designed moulds on a pneu-
matic, electrically heated, laboratory-scale, ring-making
machine. The moulds used for rod insert rings incorpo-
rate three pins that create a 3.0-mm wide bore at points
evenly spaced around the ring (Fig. 1). Heating at
80 °C for 3 min cured the rings. Ring dimensions were
56.5 and 7.6 mm overall and cross-sectional diameter,
respectively; with insert dimensions 7.6 × 3.0-mm length
and cross-sectional diameter, respectively.
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Swelling and dye uptake testing of drug-free PVC-covered
rod inserts
Covered rods were immersed in 10 mL SVF. Weight change
was assessed daily over the first 14 days and then on every
other day through to day 28, with complete replacement of the
media. Fluid ingression into the covered rods was investigated
by immersing rods in 10 mL SVF containing 20 μg/mLmeth-
ylene blue dye. Photographs of the rods were taken daily for
7 days and then weekly thereafter. Rod inserts were examined
for appearance and defects using a Nikon TE300 ECLIPSE
inverted microscope with image capture by a DXM1200 dig-
ital still camera using ACT-1 software for image processing.
HPLC analysis
All analyses were conducted on a LUNA C18 5 μm column
(150×4.6 mm). JNJ peptide was separated using a gradient
method varying 0.05 % TFA in water (A) and 0.05 % TFA in
acetonitrile (B) over 40 min from 95 % A, 5 % B to 10 % A,
90 % B. A flow rate of 1 mL/min and column temperature of
50 °C was maintained throughout with detection at 215 nm.
Under these conditions, JNJ peptide exhibited a mean reten-
tion time of 25.6 min.
T-1249 was separated using a gradient method with detec-
tion at 220 nm. The total flow rate was maintained at 1 mL/
min while the mobile phase components 0.1 % TFA in water
(A) and 0.08 % TFA in ACN (B) were varied over 12 min
from 57 % A, 43 % B to 53 % A, 47 % B. The column
temperature was maintained at 30 °C throughout. T-1249
displayed a mean retention time of 5.4 min. A series of cali-
bration standards was run with each set of release samples and
the concentrations of peptide calculated from the standard
curve run on the day. Linear regression of the combined stan-
dard curve data allowed calculation of the limit of detection
and quantification according to the ICH Q2(R1) guidelines
[28] displayed in Table 1.
In vitro release testing of rod insert vaginal rings
Rings were placed into 250-mL glass flasks with 30 mL of a
1:1 mixture of IPA and water (IPA:H2O). The first 2 days
release of JNJ peptide into IPA:H2O were performed using
20mLwhile the minimum volume required to allow complete
insert swelling was established. Samples of the release media
were taken daily for 14 days, and approximately every 2 days
thereafter, with complete media replacement each time.
Samples that could not be run on the day of analysis were
stored at 4 °C. SVF is the release medium of choice for suffi-
ciently soluble drugs as it mimics the normal vaginal fluid
most closely. Given the relatively small loading of peptide in
the rings and their poor aqueous solubility (<10 μg/mL in
SVF), release into IPA:H2O was also performed for both pep-
tides to allow easier detection and analysis, and for compara-
tive purposes.
Results
Covered rod swelling and dye uptake
The mean weight change measured after different covered
rods were immersed in SVF for 28 days is presented in
Fig. 2a. NaGlu and Zn(CH3COO)2 both exhibited weight
Fig. 1 Photographs of the
moulds used for rod insert ring
production (a), a rod insert and
empty ring (b), the ring with
inserts present (c) and a rod insert
ring after 28 days on release in
IPA:H2O (d)
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changes proportional to the amount of excipient incorporated
into the covered rod. In contrast, NaCl displayed a maximal
increase in the percentage weight change with 20 and 30 %
w/w loadings. Higher loadings showed reduced percentage
weight changes. Lactose displayed a proportional increase in
weight change to excipient loading up to a loading of 40 %
w/w with 50 % w/w rods displaying a very small percentage
weight change by comparison, 27.5 vs. 6.3 %, respectively.
NaGlu exhibited the largest percentage weight change while
lactose exhibited the smallest. As a representative example,
Fig. 2b shows the mean weight change of 3.0-mm covered
rods over 28 days for all loadings of NaGlu. In contrast, cov-
ered rods with no excipient did not display any weight change
over the 28-day period. As shown in Fig. 2b for NaGlu,
weight changes occurred over 28 days for all of the covered
rods.
Uptake of methylene blue dye in SVF (20 μg/mL) into
covered rods was assessed periodically for each insert type
to give a visual indication of the extent of swelling and fluid
access. Representative photographs of covered rods contain-
ing each type of excipient at 40 % w/w loading are presented
in Table 2. Differences in both the degree of swelling and the
level of methylene blue dye staining were observed for the
different inserts. For example, NaCl and NaGlu inserts
displayed clearly observable swelling after 1 day of being
immersed in SVF, while the lactose insert did not. Swelling
was observed with all inserts by day 7. NaGlu exhibited the
largest percentage weight gain over 28 days, five times greater
than that observed with NaCl. However, NaCl-covered rods
were more intensely coloured than equivalent NaGlu rods. A
similar pattern was observed for the Zn(CH3COO)2 compared
to lactose-containing covered rods. Again, the Zn(CH3COO)2
covered rods displayed a greater degree of weight gain but
poorer methylene blue dye uptake. In terms of intensity of
methylene blue dye staining, lactose and NaCl inserts showed
the greatest level of colouration while Zn(CH3COO)2 inserts
showed the lowest.
In vitro release of T-1249 and JNJ peptide from rod insert
rings
Cumulative in vitro release data for T-1249 into IPA:H2O over
28 days from rod insert rings containing either lactose or
Zn(CH3COO)2 at 20 and 40 % w/w are presented in Fig. 3a.
Release of T-1249 was low for each of the formulations tested.
Inserts containing 40 % w/w lactose showed a release rate that
was approximately 10-fold faster than inserts with no excipi-
ent. Zn(CH3COO)2 did not improve release at either the 20 or
40 % w/w level. NaCl and NaGlu also improved release with
40 % NaCl providing the largest impact (data not shown).
The cumulative in vitro release of JNJ peptide into
IPA:H2O measured over 28 days from rod insert rings con-
taining either NaCl or NaGlu is displayed in Fig. 3b. Release
of the peptide was improved by addition of either NaCl or
NaGlu at both 20 and 40 % w/w.
Table 3 presents the gradient of the cumulative release lines
with coefficient of determination values, the total amount of
peptide released, the percentage released and the fold-increase
in release calculated for each of the excipients. Without any
excipient addition, release of both peptides from the inserts is
minimal (2 and 6% for T-1249 and JNJ peptide, respectively).
However, for JNJ peptide, this increased to over 60% released
using 40 % w/w NaCl-loaded rods. A similar increase with
NaCl addition was seen for T-1249 in terms of the gradient of
Table 1 Limits of detection,
quantification and correlation
coefficient for T-1249 and JNJ
peptide
Peptide Release medium Limit of detection (μg/mL) Limit of quantification (μg/mL) r2
T-1249 IPA:H2O 0.45 1.36 0.9823
JNJ peptide IPA:H2O 0.47 1.43 0.9804
JNJ peptide SVF 0.60 1.81 0.9693
Fig. 2 aMean weight change of covered rods after 28 days by excipient
type and loading. bRepresentative weight change occurring over 28 days
for covered rods containing different amounts of NaGlu. All data points
are the mean of four replicates with error bars denoting standard
deviations
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release rate vs. root time, but the maximum percentage release
was still less than 20 % of the theoretical loading.
Discussion
To date, vaginal rings have mostly been used for delivery of
small, highly potent hydrophobic actives. They are not nor-
mally considered for the release of macromolecules due to the
extremely limited diffusion of large molecules through the
polymer matrix. In addition, a large quantity of drug would
be required to provide adequate loading for a human-sized
ring. For highly potent macromolecular drugs, this may rep-
resent a very significant cost per ring with the majority of the
material never released or recovered from the polymeric ma-
trix. One possible strategy to overcome these problems is the
rod insert ring [17]. Here, the ring design is modified to ac-
commodate drug-loaded inserts that are made with excipients
designed to promote release. We utilised the rod insert ring
strategy in an attempt to improve the release of two peptides in
development asmicrobicides, T-1249 and JNJ peptide, both of
which are too large for delivery from a standard ring device. In
the rod insert ring design, the choice of insert material and
excipient is critical in determining the extent of release. We
used rods composed of a similar elastomeric silicone used to
manufacture rings and considered a number of excipients
NaCl, NaGlu, lactose and Zn(CH3COOH)2. NaCl and
NaGlu have previously been used to improve release from
covered rods [14, 23]. Sugars such as sucrose and mannitol
have also been considered in this context but lactose has not
been investigated despite its widespread use in formulation as
a diluent [18, 20] There is some evidence that zinc salts have
antiviral effects, against both HIV and HSV [29–31], so we
decided to investigate its potential to improve peptide release
from the rod insert ring.
Osmotic pressure is thought to be a key driver for the re-
lease of components from silicone elastomers through pore
and crack formation [20, 32, 33]. So, we initially considered
the impact of different excipients on the swelling and fluid
ingression behaviour of the insert. The weight of blank elas-
tomeric rods immersed in SVF was measured daily over
28 days. The percentage weight change for each insert at
day 28, displayed in Fig. 2a, demonstrates that incorporation
of hydrophilic excipients can have a dramatic impact on the
extent of fluid ingress into elastomeric rods that would other-
wise remain largely unchanged in an aqueous environment.
An example of the impact of excipient loading on swelling
behaviour is displayed in Fig. 2b for NaGlu. This shows a
large loading-dependent increase in the weight of the covered
rod over 28 days. Surprisingly some covered rods showed a
drop in swelling at higher concentrations of excipient e.g.
compare lactose at 40 and 50 % w/w loading (Fig. 2a). It is
not clear why there would be a reduction in swelling seen with
an increase in salt or sugar inclusion. One possible explanation
is that mixing causes aggregation of components or they get
trapped within a silicone layer within the rod structure. This
would effectively seal off certain parts of the rod from water
ingression and may be a symptom of incomplete mixing.
Table 2 Ingress and swelling of covered rods made with 40 % w/w of each excipient over 28 days following immersion in SVF containing 20 μg/mL
methylene blue dye
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The extent of methylene blue dye uptake into covered rods
was also assessed visually by immersing the rods in a solution
of the dye in SVF (Table 2). The level of methylene blue
staining did not correlate with the degree of swelling observed
in each case. For example, despite exhibiting the largest
amount of swelling, NaGlu covered rods were amongst the
most lightly coloured. Similarly, Zn(CH3COO)2 rods were
also lightly coloured despite a reasonable degree of swelling.
In contrast, NaCl-covered rods were intensely coloured as
were lactose-covered rods despite minimal swelling.
Methylene blue can form dimers and higher order aggregates
with increasing dye concentration which impacts upon its
spectral properties [34]. In addition, adsorption of dye to a
surface can change its spectral properties [35]. Also, the ex-
tinction coefficients of methylene blue vary substantially de-
pending on whether the monomer, dimer or trimer is consid-
ered. The covered rods offer the possibility of substantial dye
adsorption as well as variation in the impact of the salt on dye
spectral properties. Finally, it is possible that dye uptake was
similar between inserts but appeared less intense due to the
volume increase upon swelling. Combined, these factors may
play a significant role in changing the relative intensity of the
methylene blue staining observedwith each rod insert. Further
studies are required to separate and quantify these effects.
The effect of all excipients, at the 20 and 40 %w/w level, on
the release of T-1249 from rod insert rings was assessed over
28 days (Table 3). Figure 3a presents data for the impact of
Zn(CH3COO)2 and lactose on T-1249 release. This demon-
strates how poor release is from a standard silicone elastomer
system. It also shows that inserts containing Zn(CH3COO)2 are
not effective at promoting release. In contrast, lactose-loaded
rods exhibited a detectable increase in release rate at 20 %, and
a large increase at 40 %. This is despite a similar level of insert
swelling observed with both compounds up to the 40 % level.
A substantial increase in release rate was also observed for rod
inserts containing NaCl and NaGlu (Table 3). A similar impact
on release rate was observed with 20 and 40 % NaCl-loaded
rods, 18-fold vs. 15-fold, respectively, which is in line with the
degree of swelling observed with blank rods, Fig. 2a.
In trying to relate the impact on release to the degree of
swelling and or dye uptake, the data for T-1249 presents a
mixed picture. Although NaCl does improve release approxi-
mately in line with the level of insert swelling observed, NaGlu
showed a lower impact on release despite exhibiting greater
swelling. Similarly, despite a similar impact on blank insert
swelling, lactose exhibited a greater impact on release than
Zn(CH3COO)2. These trends are more reflective of those seen
with dye uptake in blank rods where a more intense dye stain-
ing was observed with NaCl and lactose inserts than equivalent
inserts of NaGlu or Zn(CHCOO)2, Table 2. Zn(CH3COO)2
would be expected to produce a higher osmotic pressure than
lactose, NaCl or NaGlu as it has three ion species per molecule
dissolved compared to one for lactose and two for the other
salts. However, T-1249 does contain more acidic than basic
residues (8 vs. 4, respectively). At pH 4.2, these acidic residues
would still be largely in the positively charged state, so it is
possible that electrostatic effects associated with the use of
Zn(CH3COO)2 serve to retard the release of T-1249. This does
not explain the disparity between the release improvement ob-
served with NaCl compared to NaGlu.
Approximately 3 μg T-1249 was released on day 28. This
would correspond to a vaginal peptide concentration of ap-
proximately 40 nM, assuming similar in vivo release rates and
maximal vaginal fluid and semen volumes of 8 mL each [27,
36]. With an IC50 value of approximately 20 nM against a
wild-type HIV strain, this concentration is likely too low to
offer protection against infection [37].
NaCl and NaGlu were tested for their impact on the release
of JNJ peptide. NaGlu exhibited the largest degree of swelling
with blank inserts and NaCl as well as displaying the best
uptake of methylene blue also provided the largest improve-
ment in release of T-1249. The cumulative in vitro release of
JNJ peptide displayed in Fig. 3b shows that NaCl had a larger
Fig. 3 Cumulative release from rod insert rings of T-1249 with either 20
or 40 % lactose or Zn(CH3COO)2 (a) and JNJ peptide with 20 or 40 %
NaCl or NaGlu (b)
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impact on peptide release than NaGlu at both concentrations
tested, similar to the results seen with T-1249. In fact, 20 %
NaCl-loaded rod inserts provided higher release rates of JNJ
peptide compared to 40 % NaGlu loaded rods. From the
values displayed in Table 3, it can be seen that 40 % NaCl
inserts provided the greatest improvement in release (approx-
imately 10-fold). Given a much better baseline release for this
peptide compared to T-1249, this level of improvement is
encouraging. Similar to the T-1249 experiment, the excipient
that displayed the best swelling did not prove most effective at
promoting peptide release. Rather, the excipient displaying
better methylene blue uptake provided the greater increase in
peptide release rates. The amount of peptide released per day
at day 28 was approximately 15 μg. Again, a very rough
estimate of vaginal fluid concentration can be calculated using
the method outlined above for T-1249, yielding a predicted
concentration of 204 nM. Data on file for this peptide give an
EC50 value of 0.3 nM suggesting that this release rate may be
sufficient to provide protection assuming the release seen in
vivomatched that measured in vitro and with the same caveats
regarding the vaginal fluid volumes mentioned above.
Comparing the release of T-1249 and JNJ peptide from the
peptide-only inserts reveals a much greater release rate for JNJ
peptide (33 vs. 105 μg peptide released, respectively). The
cause of this difference in release rates is not clear. T-1249 is
slightly larger than JNJ peptide and would hence be expected
to display a slightly lower release rate, but the size of the
difference in release suggests other factors are playing a role.
Comparing the rates seen with the different excipients shows
that NaCl is by some measure the most effective at promoting
release. Lactose and sodium glutamate show a similar level of
effectiveness, and Zn(CH3COO)2 has no impact. The very low
release rates observed overall probably reflect the poor solubil-
ity of the peptides in aqueous media. However, this may not
have the same relevance in vivo where there is constant fluid
exchange and a large tissue sink for hydrophobic compounds.
The daily release values for both peptides after day 3 were
generally at or below the limit of quantification for their assays
(Table 1). However, the overall trends observed are relatively
strong and demonstrate that large molecular weight peptides
can be effectively released from a rod insert ring device. This
allows very expensive and potentially thermally labile drugs to
be incorporated into a modified vaginal ring at room temperature
using smaller quantities than would be required to make a tradi-
tional matrix or reservoir-type device. The use of the insert also
allows the release to be substantiallymodified by incorporation of
excipients designed to dissolve in aqueous environments. For
example, with 40 %NaCl incorporation, release of both peptides
was enhancedmore than 10-fold. These solids swell and dissolve
causing the development of small cracks and pores within the
elastomer. This interconnected pathway allows for the release of
macromolecules that would otherwise remain trapped in the elas-
tomer network. The rate of release can be controlled by the choice
of excipient type and loading. Although in this case, silicone
elastomers were used to make the rod inserts, there is no reason
why other suitable polymeric systems could not be considered.
Table 3 Release rates,
coefficient of determination
values, total peptide release and
relative increase seen in the
cumulative release of T-1249
and JNJ peptide into IPA:H2O
plotted against the square root of
time for different rod insert
formulations
Formulation Gradient of the
cumulative
release linea
R2 value Total peptide
released (μg)b
% releasedc Fold increasea
T-1249 only 3 0.9550 33 2 –
20 % Zn(CH3COO)2 3 0.9490 25 1 0
40 % Zn(CH3COO)2 3 0.9693 27 2 0
20 % lactose 6 0.9140 58 3 2
40 % lactose 29 0.9889 242 14 10
20 % NaCl 53 0.9804 236 14 18
40 % NaCl 44 0.9898 257 15 15
20 % NaGlu 10 0.9841 76 4 3
40 % NaGlu 15 0.9826 163 10 5
JNJ peptide only 24 0.8874 105 6 –
20 % NaCl 116 0.9978 493 29 5
40 % NaCl 261 0.9912 1063 62 11
20 % NaGlu 32 0.9770 133 8 1
40 % NaGlu 88 0.9898 385 23 4
a Values rounded to the nearest whole number
b Values quoted to the nearest μg
c The percentage peptide released was calculated based on a theoretical loading of 1705 μg per ring and quoted to
the nearest per cent. This figure is 1 % of the mean weight of the total rod insert weight per ring, used in the
peptide-only rings for the JNJ peptide. Weights for the T-1249 1 % loaded rod inserts are not available, so the
mean weight of the total rod insert per ring for the peptide was used
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